B Fabris1, S Bernardi2, C Trombetta3. 1. Division of Internal Medicine, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. b.fabris@fmc.units.it. 2. Division of Internal Medicine, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy. 3. Division of Urology, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Abstract
PURPOSE: Gender identity is the sense one has of being male or female. Gender dysphoria (GD) refers to the distress caused by the incongruence between gender identity and biological sex in gender-nonconforming individuals. Cross-sex hormone therapy (CHT) aims at easing GD, improving well-being, and quality of life of gender-nonconforming individuals. This can be achieved by inducing and maintaining the desired-sex characteristics in accordance with the specific aspirations and expectations of each individual. Nevertheless, CHT can be associated with potentially serious long-term complications. METHODS: Here, we review when, how, and how long to prescribe CHT to adult transsexuals as well as what to expect and monitor once it has been initiated. RESULTS: In recent years, transsexualism has become more and more recognized and depathologized. To manage GD, National and International Standards of Care have been established. Nevertheless, the needs of transgender patients can still be ignored or dismissed. Moreover, some questions remain unanswered because of the lack of specific retrospective or prospective studies on CHT. CONCLUSION: Education and culturally sensitive training must be supplied to healthcare professionals to overcome the existing issues on GD management and change the perspectives of transsexual people.
PURPOSE: Gender identity is the sense one has of being male or female. Gender dysphoria (GD) refers to the distress caused by the incongruence between gender identity and biological sex in gender-nonconforming individuals. Cross-sex hormone therapy (CHT) aims at easing GD, improving well-being, and quality of life of gender-nonconforming individuals. This can be achieved by inducing and maintaining the desired-sex characteristics in accordance with the specific aspirations and expectations of each individual. Nevertheless, CHT can be associated with potentially serious long-term complications. METHODS: Here, we review when, how, and how long to prescribe CHT to adult transsexuals as well as what to expect and monitor once it has been initiated. RESULTS: In recent years, transsexualism has become more and more recognized and depathologized. To manage GD, National and International Standards of Care have been established. Nevertheless, the needs of transgender patients can still be ignored or dismissed. Moreover, some questions remain unanswered because of the lack of specific retrospective or prospective studies on CHT. CONCLUSION: Education and culturally sensitive training must be supplied to healthcare professionals to overcome the existing issues on GD management and change the perspectives of transsexual people.
Authors: K Wierckx; E Elaut; E Declercq; G Heylens; G De Cuypere; Y Taes; J M Kaufman; G T'Sjoen Journal: Eur J Endocrinol Date: 2013-09-13 Impact factor: 6.664
Authors: A W F T Toorians; M C L G D Thomassen; S Zweegman; E J P Magdeleyns; G Tans; L J G Gooren; J Rosing Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer Journal: Diabetes Care Date: 2011-03-08 Impact factor: 19.112
Authors: E Castellano; C Crespi; C Dell'Aquila; R Rosato; C Catalano; V Mineccia; G Motta; E Botto; C Manieri Journal: J Endocrinol Invest Date: 2015-12 Impact factor: 4.256
Authors: Emilia M Jalil; Beatriz Grinsztejn; Luciane Velasque; Alessandra Ramos Makkeda; Paula M Luz; Ronaldo I Moreira; Luciana Kamel; Nilo M Fernandes; Ana Cristina G Ferreira; Brenda Hoagland; Sandra Wagner; Albert Liu; Willi McFarland; Susan Buchbinder; Valdilea G Veloso; Erin Wilson Journal: J Acquir Immune Defic Syndr Date: 2018-12-01 Impact factor: 3.731
Authors: Jesús Manuel García-Acosta; Rosa María San Juan-Valdivia; Alfredo David Fernández-Martínez; Nieves Doria Lorenzo-Rocha; Maria Elisa Castro-Peraza Journal: Int J Environ Res Public Health Date: 2019-12-19 Impact factor: 3.390
Authors: Lucas Foster Skewis; Ingrid Bretherton; Shalem Y Leemaqz; Jeffrey D Zajac; Ada S Cheung Journal: Front Endocrinol (Lausanne) Date: 2021-07-29 Impact factor: 5.555